Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer.
Breast cancer
F-18 FDG
SUVmax
neoadjuvant chemotherapy
Journal
European journal of breast health
ISSN: 2587-0831
Titre abrégé: Eur J Breast Health
Pays: Turkey
ID NLM: 101709357
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
18
01
2023
accepted:
19
02
2023
medline:
8
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
The role of baseline and post-treatment standardized uptake value (SUV Thirty patients with invasive ductal breast cancer were included in this retrospective study. F-18 fluorodeoxyglucose (FDG) positron emission tomography/computerized tomography (PET/CT) examinations were performed before and after NAC. Pretreatment SUV The mean age of the 30 patients included in the study was 51.2±11.98 years. In the study-defined grouping, 13 patients (43.3%) were nonresponders and 17 patients (56.7%) were responders. ΔSUV F-18 FDG PET/CT was an effective method in evaluating the treatment response after NAC in breast cancer, and ΔSUV
Identifiants
pubmed: 37025574
doi: 10.4274/ejbh.galenos.2023.2023-1-3
pii: 59071
pmc: PMC10071889
doi:
Types de publication
Journal Article
Langues
eng
Pagination
159-165Informations de copyright
©Copyright 2023 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
J Clin Oncol. 2009 Feb 1;27(4):535-41
pubmed: 19075273
Chin J Cancer Res. 2013 Aug;25(4):397-404
pubmed: 23997526
J Nucl Med. 2003 Nov;44(11):1806-14
pubmed: 14602864
AJR Am J Roentgenol. 2016 Apr;206(4):846-55
pubmed: 27003053
Front Oncol. 2021 Jan 05;10:592556
pubmed: 33469514
Eurasian J Med. 2019 Jun;51(2):154-159
pubmed: 31258356
Br J Cancer. 1998 Feb;77(4):621-6
pubmed: 9484820
Int J Clin Oncol. 2012 Jun;17(3):276-82
pubmed: 21830087
Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1915-24
pubmed: 17579854
Nucl Med Commun. 2021 Mar 1;42(3):315-324
pubmed: 33315727
Acta Radiol. 2011 Feb 1;52(1):21-8
pubmed: 21498321
Breast. 2013 Oct;22(5):691-7
pubmed: 23414930
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1551-7
pubmed: 19326117
Eur J Cancer. 2013 May;49(7):1539-45
pubmed: 23369464
J Clin Oncol. 2006 Dec 1;24(34):5366-72
pubmed: 17088570
Breast Cancer Res Treat. 2012 Jan;131(2):357-69
pubmed: 21960111
Tumour Biol. 2014 Nov;35(11):11613-20
pubmed: 25139100
Jpn J Clin Oncol. 2008 Apr;38(4):250-8
pubmed: 18407934
J Nucl Med. 2002 Apr;43(4):500-9
pubmed: 11937594
Eur J Nucl Med. 2000 Jul;27(7):861-6
pubmed: 10952499
Acta Radiol. 2012 Jul;53(6):628-36
pubmed: 22761341
Asia Ocean J Nucl Med Biol. 2016 Winter;4(1):3-11
pubmed: 27904868
Breast Cancer Res Treat. 2012 Jan;131(2):517-25
pubmed: 22037787
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
J Clin Oncol. 2012 Sep 10;30(26):3242-9
pubmed: 22649152
Ann Surg Oncol. 2010 Jan;17(1):247-53
pubmed: 19777177
Rev Esp Med Nucl Imagen Mol. 2014 Jan-Feb;33(1):14-21
pubmed: 23809513